---
title: Angiotensin-Converting Enzyme Polymorphism and Acute Renal Failure (ECAREA)
nct_id: NCT00316576
overall_status: TERMINATED
sponsor: University Hospital, Caen
study_type: OBSERVATIONAL
primary_condition: Kidney Failure, Acute
countries: France
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00316576.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00316576"
ct_last_update_post_date: 2008-01-17
last_seen_at: "2026-05-12T06:49:37.585Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Angiotensin-Converting Enzyme Polymorphism and Acute Renal Failure (ECAREA)

**Official Title:** Evaluation of the Impact of the Angiotensin-Converting Enzyme Insertion/Deletion Polymorphism on the Development of Acute Renal Failure in Critically Ill Patients

**NCT ID:** [NCT00316576](https://clinicaltrials.gov/study/NCT00316576)

## Key Facts

- **Status:** TERMINATED
- **Why Stopped:** The study was stopped on november 2006 after inclusion was fulfilled
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 160
- **Lead Sponsor:** University Hospital, Caen
- **Conditions:** Kidney Failure, Acute, Critical Illness
- **Start Date:** 2006-05
- **Completion Date:** 2006-11
- **CT.gov Last Update:** 2008-01-17

## Brief Summary

Associations between angiotensin-converting enzyme gene polymorphism and occurrence and outcome of ARDS, and with respiratory complications post cardiopulmonary bypass have already been demonstrated. Based on physiological effects of angiotensin II, we hypothesized that the I allele of the angiotensin-converting enzyme Insertion/Deletion polymorphism may be associated with a higher risk of acute renal failure in critically ill patients.

## Detailed Description

Associations between angiotensin-converting enzyme gene polymorphism and occurrence and outcome of ARDS, and with respiratory complications post cardiopulmonary bypass have already been demonstrated. Based on physiological effects of angiotensin II, we hypothesized that the I allele of the angiotensin-converting enzyme Insertion/Deletion polymorphism may be associated with a higher risk of acute renal failure in critically ill patients.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Age \> 18 yrs
* ICU stay \> 48 hours

Exclusion Criteria:

* Age \< 18 yrs
* Creatinine \> 180 µmol/L
* Absence of consent
```

## Interventions

- **Blood sampling for PCR** (PROCEDURE)

## Primary Outcomes

- **Incidence of ARF** _(time frame: During ICU stay)_

## Secondary Outcomes

- **Mortality** _(time frame: ICU and Hospital mortality)_

## Locations (1)

- Medical Intensive care Unit; Caen University Hospital, Caen, France

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.whyStopped` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.medical intensive care unit; caen university hospital|caen||france` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00316576.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00316576*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*